FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...

Christine Magnus Moore, RN, BSN, CPON has worked in the nursing field for over twenty-five years, with more than fourteen years in oncology. She has a Master’s Certification in caring for teenagers ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia vera. FDA approves BESREMi (ropeginterferon ...

Chasity Washington MPH, CHES | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, reviews the venous thromboembolism (VTE) data behind ...

Having recently moderated a case-based roundtable discussion on triple-negative breast cancer, Iorio shares her clinical ...

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, ...

FDA approves daraxonrasib, a first-in-class daily oral RAS inhibitor, doubling survival in metastatic pancreatic ...

C, discussed the collaborative care model and the vital role of PAs in managing day-to-day oncology care. Physician ...